The Purpose of This Study is to Evaluate the Safety and Efficacy of D-MNA in Adult Patients With Nodular Basal Cell Carcinoma
Phase 2
Recruiting
- Conditions
- Nodular Basal Cell Carcinoma
- Interventions
- Drug: D-MNA 200 mcgDrug: D-MNA 100 mcgOther: Placebo
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-09-23
- Lead Sponsor
- SkinJect, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06608238
- Locations
- 🇺🇸
Site #4, Fresno, California, United States
🇺🇸Site #6, San Diego, California, United States
🇺🇸Site #3, Highlands, New Jersey, United States
Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)
Phase 1
Active, not recruiting
- Conditions
- Basal Cell Carcinoma
- Interventions
- Combination Product: Doxorubicin-containing MNADrug: Placebo-containing MNA
- First Posted Date
- 2021-06-16
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- SkinJect, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04928222
- Locations
- 🇺🇸
Beer Dermatology, West Palm Beach, Florida, United States
🇺🇸New York and Presbyterian Hospital, New York, New York, United States
Dose Escalation Trial to Evaluate Dose Limiting Toxicity/Maximum Tolerated Dose of Microneedle Arrays Containing Doxorubicin (D-MNA) in Basal Cell Carcinoma (BCC)
Phase 1
Terminated
- Conditions
- Basal Cell Carcinoma
- Interventions
- Drug: 100 µg doxorubicin-containing MNADrug: Placebo-containing MNADrug: 200 µg doxorubicin-containing MNADrug: 25 µg doxorubicin-containing MNADrug: 50 µg doxorubicin-containing MNA
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- SkinJect, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT03646188
- Locations
- 🇺🇸
The Center for Clinical and Cosmetic Research, Aventura, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath